The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers
Active 4
  • 1
    Menziuso, Richard
    Controller born in April 1975
    Individual (11 offsprings)
    Officer
    2022-11-01 ~ dissolved
    OF - Director → CIF 0
  • 2
    Hussain, Iqbal
    Lawyer born in February 1981
    Individual (13 offsprings)
    Officer
    2021-01-29 ~ dissolved
    OF - Director → CIF 0
  • 3
    CENTESSA LIMITED - 2022-11-22
    UNITED MEDICINES BIOPHARMA (MIDCO) LIMITED - 2021-02-17
    3rd Floor, 1 Ashley Road, Altrincham, Cheshire, United Kingdom
    Active Corporate (5 parents, 8 offsprings)
    Person with significant control
    2022-12-20 ~ dissolved
    PE - Ownership of shares – 75% or more → CIF 0
    PE - Ownership of voting rights - 75% or more → CIF 0
    PE - Right to appoint or remove directors → CIF 0
  • 4
    3rd Floor, 1 Ashley Road, Altrincham, Cheshire, United Kingdom
    Active Corporate (7 parents, 2461 offsprings)
    Total Assets Less Current Liabilities (Company account)
    1 GBP2016-09-30
    Officer
    2021-11-30 ~ dissolved
    OF - Secretary → CIF 0
Ceased 9
  • 1
    Saha, Saurabh, Dr
    Ceo born in November 1976
    Individual (1 offspring)
    Officer
    2021-01-29 ~ 2021-11-30
    OF - Director → CIF 0
  • 2
    Chao, David Min
    Chief Administrative Officer, Centessa Pharmaceuti born in May 1967
    Individual (2 offsprings)
    Officer
    2022-06-17 ~ 2023-08-18
    OF - Director → CIF 0
  • 3
    Luthringer, Remy Henri
    Ceo born in November 1960
    Individual
    Officer
    2019-04-16 ~ 2021-01-29
    OF - Director → CIF 0
  • 4
    De Rubertis, Francesco
    Investor born in January 1970
    Individual (19 offsprings)
    Officer
    2018-10-05 ~ 2021-01-29
    OF - Director → CIF 0
  • 5
    Thorell, Marella
    Accountant born in March 1967
    Individual (4 offsprings)
    Officer
    2021-01-29 ~ 2022-07-31
    OF - Director → CIF 0
  • 6
    Accardi, Mario Alberto, Dr
    Chief Executive Officer born in February 1986
    Individual (7 offsprings)
    Officer
    2019-01-02 ~ 2021-01-29
    OF - Director → CIF 0
  • 7
    Ratti, Emiliangelo Ratti, Dr
    Pharmaceutical Consultant born in November 1954
    Individual
    Officer
    2020-11-02 ~ 2021-01-29
    OF - Director → CIF 0
  • 8
    Grainger, David John, Dr
    Director born in October 1966
    Individual (35 offsprings)
    Officer
    2021-11-30 ~ 2023-08-18
    OF - Director → CIF 0
  • 9
    CENTESSA PHARMACEUTICALS LIMITED - 2021-05-14
    UNITED MEDICINES BIOPHARMA LIMITED - 2021-02-17
    3rd Floor, 1 Ashley Road, Altrincham, Cheshire, United Kingdom
    Active Corporate (9 parents, 1 offspring)
    Person with significant control
    2021-01-29 ~ 2022-12-20
    PE - Ownership of shares – 75% or more → CIF 0
    PE - Ownership of voting rights - 75% or more → CIF 0
    PE - Right to appoint or remove directors → CIF 0
parent relation
Company in focus

CENTESSA PHARMACEUTICALS (OREXIA) LIMITED

Previous names
OREXIA THERAPEUTICS LIMITED - 2023-04-03
OREXIA LIMITED - 2021-02-24
Standard Industrial Classification
72110 - Research And Experimental Development On Biotechnology
Brief company account
Average Number of Employees
32020-01-01 ~ 2020-12-31
32018-10-05 ~ 2019-12-31
Intangible Assets
734,589 GBP2020-12-31
826,413 GBP2019-12-31
Property, Plant & Equipment
14,499 GBP2020-12-31
Debtors
Current
1,773,006 GBP2020-12-31
139,426 GBP2019-12-31
Cash at bank and in hand
1,522,790 GBP2020-12-31
3,303,829 GBP2019-12-31
Current Assets
3,295,796 GBP2020-12-31
3,443,255 GBP2019-12-31
Creditors
Current, Amounts falling due within one year
-1,706,659 GBP2020-12-31
-849,745 GBP2019-12-31
Net Current Assets/Liabilities
1,589,137 GBP2020-12-31
2,593,510 GBP2019-12-31
Net Assets/Liabilities
2,338,225 GBP2020-12-31
3,419,923 GBP2019-12-31
Equity
Called up share capital
546 GBP2020-12-31
536 GBP2019-12-31
Share premium
9,210,628 GBP2020-12-31
6,958,303 GBP2019-12-31
Retained earnings (accumulated losses)
-6,872,949 GBP2020-12-31
-3,538,916 GBP2019-12-31
Equity
2,338,225 GBP2020-12-31
3,419,923 GBP2019-12-31
Profit/Loss
Retained earnings (accumulated losses)
-3,334,033 GBP2020-01-01 ~ 2020-12-31
-3,538,916 GBP2018-10-05 ~ 2019-12-31
Profit/Loss
-3,334,033 GBP2020-01-01 ~ 2020-12-31
-3,538,916 GBP2018-10-05 ~ 2019-12-31
Issue of Equity Instruments
Called up share capital
10 GBP2020-01-01 ~ 2020-12-31
536 GBP2018-10-05 ~ 2019-12-31
Issue of Equity Instruments
2,252,335 GBP2020-01-01 ~ 2020-12-31
6,958,839 GBP2018-10-05 ~ 2019-12-31
Property, Plant & Equipment - Depreciation rate used
Plant and equipment
252020-01-01 ~ 2020-12-31
Intangible Assets - Gross Cost
Patents/Trademarks/Licences/Concessions
918,237 GBP2020-12-31
918,237 GBP2019-12-31
Intangible Assets - Accumulated Amortisation & Impairment
Patents/Trademarks/Licences/Concessions
183,648 GBP2020-12-31
91,824 GBP2019-12-31
Intangible Assets
Patents/Trademarks/Licences/Concessions
734,589 GBP2020-12-31
826,413 GBP2019-12-31
Property, Plant & Equipment - Gross Cost
Office equipment
19,332 GBP2020-12-31
Property, Plant & Equipment - Increase From Depreciation Charge for Year
Office equipment, Owned/Freehold
4,833 GBP2020-01-01 ~ 2020-12-31
Property, Plant & Equipment - Accumulated Depreciation & Impairment
Office equipment
4,833 GBP2020-12-31
Property, Plant & Equipment
Office equipment
14,499 GBP2020-12-31
Other Debtors
Current
1,767,505 GBP2020-12-31
134,453 GBP2019-12-31
Prepayments/Accrued Income
Current
5,501 GBP2020-12-31
4,973 GBP2019-12-31
Trade Creditors/Trade Payables
Current
89,052 GBP2020-12-31
27,521 GBP2019-12-31
Taxation/Social Security Payable
Current
17,553 GBP2020-12-31
3,604 GBP2019-12-31
Other Creditors
Current
479 GBP2019-12-31
Accrued Liabilities/Deferred Income
Current
600,054 GBP2020-12-31
818,141 GBP2019-12-31
Creditors
Current
1,706,659 GBP2020-12-31
849,745 GBP2019-12-31
Number of Shares Issued (Fully Paid)
Class 1 ordinary share
1,199,151 shares2020-12-31
Par Value of Share
Class 1 ordinary share
0.00012020-01-01 ~ 2020-12-31
Number of Shares Issued (Fully Paid)
Class 2 ordinary share
680,980 shares2020-12-31
Par Value of Share
Class 2 ordinary share
0.00012020-01-01 ~ 2020-12-31
Number of Shares Issued (Fully Paid)
Class 3 ordinary share
4,200,000 shares2020-12-31
Par Value of Share
Class 3 ordinary share
0.00012020-01-01 ~ 2020-12-31
  • CENTESSA PHARMACEUTICALS (OREXIA) LIMITED
    Info
    OREXIA THERAPEUTICS LIMITED - 2023-04-03
    OREXIA LIMITED - 2021-02-24
    Registered number 11607013
    3rd Floor 1 Ashley Road, Altrincham, Cheshire WA14 2DT
    Private Limited Company incorporated on 2018-10-05 and dissolved on 2024-12-17 (6 years 2 months). The company status is Dissolved.
    The last date of confirmation statement was made at 2024-02-07
    CIF 0
child relation
Offspring entities and appointments
Active 0
  • Not found in our database.

qrcode

Privacy notice

Terms and conditions

© 2022-2025 Polylogarithmic Technology Ltd. All rights reserved.
Contains public sector information retrieved at 24 April 2025 and licensed under the Open Government Licence v3.0.